A 71-year-old with a vitamin B12 reading that looks perfectly fine on paper might still be losing ground inside the brain. That is the unsettling implication of a study from the University of California, San Francisco, published in May 2026 in Annals of Neurology, which found that the form of B12 the body can actually use may matter far more than the number most doctors check.
The UCSF-led analysis followed 231 cognitively healthy older adults drawn from the university’s BrANCH cohort. Their average age was roughly 71, and their average total serum B12 sat at approximately 414.8 pmol/L, nearly three times the commonly used U.S. lower reference limit of 148 pmol/L. By any standard lab report, these people were not deficient. Yet when researchers measured holotranscobalamin, the biologically active fraction of B12 that cells can actually absorb and use, a different picture emerged. Participants with lower active B12 showed slower cognitive processing speed, delayed visual evoked potentials (electrical signals traveling through the brain’s visual pathways), and a heavier burden of white-matter lesions on MRI.
“These results suggest that conventional serum B12 measurements may be insufficient to detect functionally meaningful deficits in the aging nervous system,” the study authors wrote, noting that the associations held even after adjusting for age, sex, and other potential confounders.
In other words, the brain was registering damage that the standard blood test missed.
Why the standard test may not be enough
Most clinical labs in the United States report total serum B12, a measure that captures both the active form bound to transcobalamin and a larger inactive fraction bound to haptocorrin. The UCSF findings suggest that total B12 can look reassuring while the portion the nervous system depends on runs low. This is not an entirely new idea, but the study adds unusually direct evidence: functional brain measures (visual evoked potentials) and structural imaging (white-matter lesion volume) both tracked with active B12 in a cohort where total B12 was well above the floor.
Research on older populations suggests the disconnect between total and active B12 may be more common than many clinicians assume. Studies have found that a substantial proportion of older adults with total B12 levels in the normal range still show biochemical signs of tissue-level deficiency, such as elevated methylmalonic acid, indicating that the body is not getting enough usable B12 even when the headline number looks adequate. The UCSF cohort, with its average total B12 of roughly 414.8 pmol/L, illustrates exactly this gap: group-level sufficiency on the standard test coexisted with individual-level variation in the active fraction that predicted real brain outcomes.
The concept has roots stretching back decades. A landmark 1988 report in the New England Journal of Medicine described patients who developed neurological and neuropsychiatric symptoms of B12 deficiency without the expected anemia or enlarged red blood cells. That paper helped shift clinical attention toward metabolic markers like methylmalonic acid and homocysteine, which rise when tissues are starved of usable B12 even if total serum levels appear adequate. The UCSF study extends that logic by showing that even among people with no cognitive diagnosis and no flagged lab values, the active fraction of B12 still predicts measurable brain outcomes.
Supporting evidence from earlier research
The UCSF results do not stand alone. A longitudinal study of community-dwelling older adults, published in Neurology, found that baseline B12 status predicted the rate of subsequent brain volume loss over a five-year period. Participants with lower B12 and higher homocysteine experienced faster atrophy in regions vulnerable to age-related decline, reinforcing the link between one-carbon metabolism and structural brain aging.
The VITACOG randomized controlled trial offered an interventional dimension. In that study, a combination of B12, folate, and B6 slowed brain atrophy in older adults with mild cognitive impairment by lowering homocysteine. A companion analysis showed that the cognitive benefits concentrated among participants who started with elevated homocysteine, suggesting the effect depends on individual metabolic context rather than applying universally. Together with the UCSF data, these studies sketch a coherent biological story: B12 supports myelin maintenance and methylation reactions critical to neural health, and subtle shortfalls can show up as white-matter damage and accelerated shrinkage well before a person notices memory problems.
What the study cannot tell us
The UCSF study is observational. It can demonstrate that lower active B12 correlates with signs of neural injury, but it cannot prove that raising active B12 would reverse or prevent that damage. The researchers did not test a supplement intervention, and without randomized assignment to different B12 levels, the possibility remains that some unmeasured factor, such as diet quality, absorption problems, or underlying health conditions, both lowers active B12 and independently harms the brain.
The study also did not propose a specific holotranscobalamin threshold to replace the current 148 pmol/L floor used for total B12. That leaves clinicians without a validated new cutoff, and any attempt to extrapolate target numbers from a single cohort of 231 people would outrun the data.
Broader trial evidence on B12 supplementation and cognition remains mixed. The NIH’s Office of Dietary Supplements has summarized multiple randomized controlled trials in which B12 alone, or combined with folate, did not consistently improve memory or global cognitive scores in unselected older populations. The VITACOG trial showed structural brain benefits, but it used three B vitamins together, not B12 in isolation, and enrolled people who already had mild cognitive impairment. Whether the same approach would help the kind of cognitively intact adults in the UCSF cohort is an open question. No large trial has yet tested high-dose B12 targeted specifically to people with low active levels but normal totals.
There is also no professional consensus on whether holotranscobalamin should replace total B12 as the preferred clinical test. Total B12 remains the standard because it is well established, relatively inexpensive, and backed by decades of reference data. Shifting diagnostic practice would require validation in larger, more diverse populations and agreement among professional societies on new reference ranges.
Why “normal” B12 deserves a second look after age 65
None of this research tells any individual to start taking supplements on their own. The distance between “lower active B12 tracks with worse brain markers in a research cohort” and “taking more B12 will protect your brain” is real and important. But the findings do suggest a practical first step: older adults concerned about cognitive decline can ask a physician whether testing for holotranscobalamin, or related metabolic markers like methylmalonic acid and homocysteine, would add useful information beyond a standard total B12 reading. These tests are commercially available and can reveal whether the body is actually using the B12 circulating in the blood.
For people with risk factors for poor B12 absorption, such as long-term use of proton pump inhibitors or other acid-suppressing medications, a history of gastrointestinal surgery, or strict vegan diets, this kind of testing may be especially informative. The UCSF data suggest that total B12 alone can paint an incomplete picture, and requesting a more detailed workup is a low-risk way to get more specific information.
Perhaps the most important implication is philosophical as much as medical. “Normal” lab values are not fixed truths. They are statistical boundaries, set by expert committees based largely on population distributions and the need to detect overt disease. The current U.S. lower reference limit for B12 was designed primarily to catch frank deficiency states that cause anemia and obvious neurological syndromes, not to guarantee optimal cognitive aging over decades. As research like the UCSF study probes how micronutrient status interacts with brain structure and function at finer resolution, the conversation between patients and clinicians may need to shift from a simple pass-or-fail reading toward a more personalized assessment, one where “normal” is the beginning of the discussion rather than the end of it.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
